Literature DB >> 18854518

Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate.

K Owczarczyk, M Hellmann, G Fliedner, T Röhrs, K Maizus, D Passon, M Hallek, A Rubbert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18854518     DOI： 10.1136/ard.2007.087023

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  10 in total

1.  Anti-interleukin 6: first line in rheumatoid arthritis?

Authors:  Luciana Marti; Morton Scheinberg
Journal:  Clin Rheumatol       Date:  2009-05-05       Impact factor: 2.980

2.  [Recommendations for use of rituximab in patients with rheumatoid arthritis].

Authors:  A Rubbert-Roth; G R Burmester; T Dörner; A Gause
Journal:  Z Rheumatol       Date:  2014-03       Impact factor: 1.372

Review 3.  The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Young Ho Lee; Sang-Cheol Bae; Gwan Gyu Song
Journal:  Rheumatol Int       Date:  2010-05-16       Impact factor: 2.631

4.  Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis.

Authors:  Joerg Christoph Henes; Joerg Schedel; Lothar Kanz; Ina Koetter
Journal:  Rheumatol Int       Date:  2009-12-12       Impact factor: 2.631

5.  A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy.

Authors:  Hongjie Wang; Ying Liu; Zong-Yi Li; Xiaolong Fan; Akseli Hemminki; André Lieber
Journal:  Blood       Date:  2009-11-12       Impact factor: 22.113

6.  [How effective is rituximab in rheumatoid arthritis?: lessons learned from clinical practice].

Authors:  W A Schmidt; B Schicke; A Krause; D Wernicke
Journal:  Z Rheumatol       Date:  2010-06       Impact factor: 1.372

Review 7.  Biologic monotherapy in the treatment of rheumatoid arthritis.

Authors:  Jacqueline Detert; Pascal Klaus
Journal:  Biologics       Date:  2015-05-14

8.  Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients.

Authors:  Joerg Wendler; Gerd R Burmester; Helmut Sörensen; Andreas Krause; Constanze Richter; Hans-Peter Tony; Andrea Rubbert-Roth; Peter Bartz-Bazzanella; Siegfried Wassenberg; Iris Haug-Rost; Thomas Dörner
Journal:  Arthritis Res Ther       Date:  2014-03-26       Impact factor: 5.156

9.  Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders.

Authors:  Celine Kaegi; Benjamin Wuest; Jens Schreiner; Urs C Steiner; Alessandra Vultaggio; Andrea Matucci; Catherine Crowley; Onur Boyman
Journal:  Front Immunol       Date:  2019-09-06       Impact factor: 7.561

Review 10.  Rituximab for the treatment of multiple sclerosis: a review.

Authors:  Clara Grazia Chisari; Eleonora Sgarlata; Sebastiano Arena; Simona Toscano; Maria Luca; Francesco Patti
Journal:  J Neurol       Date:  2021-01-08       Impact factor: 6.682
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.